Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Overview of attention for article published in Journal of Clinical Oncology, January 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 13 news outlets
twitter: 50 X users
patent: 3 patents

facebook: 1 Facebook page
reddit: 1 Redditor
guideline: 1 clinical guideline source

Readers on

mendeley: 319 Mendeley

So far, Altmetric has seen 53 X posts from 50 X users, with an upper bound of 187,073 followers.

@grok @venice_mind @Kevin_McKernan @MediGenomics @HighScienceX @CannMedEvents @Jikkyleaks - APR-246: Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes, https://t.co/opqrfKsjXt, investigate @grok

RT @aljurf100: Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes | Journal of Clinical Oncology https://t.co/…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 49 additional X posts.